UroGen Pharma URGN Cash Flow Statement (2016-2026)

NASDAQ URGN
$44.09 -0.79 (-1.76%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

UroGen Pharma Quarterly Cash Flow Statement

Periods 39 quarters
Latest Jun 2026

UroGen Pharma reported cash from operations of -$33.01M and free cash flow of -$34.27M for the quarter ended Jun 2026, up 17.1% year over year. This cash flow statement covers 39 quarters of results from Dec 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-30.21M-1.85M-28.39M-26.69M-25.83M-2.27M-30.21M-24.14M-21.88M0.52M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M9.00M-23.57M-14.35M
Share-based CompensationStock Comp.
5.51M5.36M2.95M2.82M2.44M2.37M2.29M2.22M2.22M2.61M2.76M3.56M3.49M3.30M3.07M2.73M17.60M3.13M39.10M39.00M
Gains from Investment SecuritiesGains Investment
Asset Writedowns and ImpairmentWritedown
0.35M0.26M
Cash from OperationsCash from Ops.
-18.48M-20.07M-24.00M-24.20M-17.61M-21.75M-25.81M-20.27M-17.30M-13.00M-31.73M-23.75M-27.66M-13.62M-42.02M-39.83M-42.27M-38.33M-45.32M-33.01M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.23M0.24M0.28M0.20M0.59M0.68M0.40M0.35M0.22M0.05M-0.96M0.22M2.29M1.34M0.77M0.87M0.16M0.30M1.97M-0.80M
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.20M0.21M0.21M0.20M0.20M0.22M0.22M0.20M0.20M0.19M0.12M0.10M0.10M0.03M0.10M0.10M0.10M0.07M0.10M0.10M
Change in Working Capital
Change in ReceivablesChange Receivables
-1.73M3.93M-2.22M2.10M-2.17M3.27M-0.21M3.01M-2.66M2.60M-1.28M3.26M5.39M-2.50M-0.66M0.01M0.05M13.38M22.33M33.34M
Change in InventoryChange Inventory
0.39M1.02M-0.08M0.56M0.17M-0.28M1.14M-0.48M0.01M0.67M1.57M0.20M0.15M1.63M-1.64M-0.46M1.21M8.12M4.46M3.67M
Change in Accured ExpensesChange Accured Exp.
-0.30M0.47M-2.17M-1.28M0.71M4.05M4.75M-0.73M-2.32M2.46M-5.83M13.04M-4.07M7.75M-3.60M7.13M-4.79M4.20M7.63M4.60M
Investing Activities
Capital ExpendituresCapex
0.55M-0.55M0.17M0.28M0.56M0.27M0.42M-0.34M-0.77M-0.01M-0.94M-0.42M-0.30M0.22M-0.22M0.43M5.96M-1.60M2.33M1.27M
Change in Acquisitions & DivestmentsChange Acquisitions
18.33M9.63M13.62M-0.09M27.67M23.12M30.47M3.73M11.33M3.54M13.52M12.08M12.14M69.97M40.43M30.34M40.21M28.27M4.15M1.73M
Cash from Investing ActivitiesCash from Investing
10.66M9.12M13.60M-0.15M-35.49M23.11M6.27M3.72M0.40M-11.34M13.52M12.00M-106.75M60.62M-25.96M28.41M31.40M27.72M-20.69M1.67M
Financing Activities
Other financing activitiesOther financing
0.00M0.02M1.12M0.38M0.67M0.14M47.89M18.64M0.03M0.30M0.30M1.34M0.18M0.89M
Cash from Financing ActivitiesCash from Financing
-0.17M-0.03M70.74M-0.08M1.10M25.37M0.67M0.14M116.08M0.04M54.66M100.28M39.61M0.07M0.03M0.30M8.27M31.32M65.20M0.50M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.59M0.41M0.53M0.28M0.12M
Net Equity Issued and RepurchasedNet Equity Issued
67.36M54.66M81.51M15.00M0.00M-0.00M8.20M31.83M
Additional items
Change in Cash
-7.98M-10.98M60.34M-24.43M-52.00M26.72M-18.87M-16.41M99.18M-24.30M36.44M88.53M-94.81M47.07M-67.95M-11.12M-2.60M20.71M-0.80M-30.83M
Free Cash FlowFCF
-19.02M-19.52M-24.16M-24.47M-18.17M-22.02M-26.23M-19.93M-16.53M-12.98M-30.80M-23.32M-27.36M-13.84M-41.81M-40.26M-48.23M-36.73M-47.65M-34.27M
Net Cash FlowNCF
-7.98M-10.98M60.34M-24.43M-52.00M26.72M-18.87M-16.41M99.18M-24.30M36.44M88.53M-94.81M47.07M-67.95M-11.12M-2.60M20.71M-0.80M-30.83M